The opportunities in data-driven medicine are promising: for patients, for the health system and for the economy. The potential of acquisition and IT-supported application of high-dimensional health data in clinical research and healthcare will for sure be leveraged in the coming years. In addition to the medical-biological perspective, a particular hot topic is to build fit-for-purpose IT-infrastructures on European, German and local scales. Key is also to assess and adapt the interplay of data-driven modern medicine with society and individual patients as beneficiaries and donors.
The consortium "DigiMed Bayern - Pilot Project for P4 Medicine in Bavaria " invites you to this year's DigiMed Bayern Symposium with national and international key players on
Professor of Medicine and Co-Director Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York City, U.S.A.
Erwin Böttinger holds dual academic appointments as Professor of Digital Health - Personalized Medicine at the Hasso Plattner Institute and University of Potsdam, Germany, and as Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York City, United States. He serves as founding director of the Digital Health Center at the Hasso Plattner Institute, Potsdam, and as founding co-director of the Hasso Plattner Institute for Digital Health at Mount Sinai, New York City. He received his M.D. degree from the University Erlangen-Nuremberg, Germany. He continued postgraduate training in the United States at Harvard Medical School and the National Cancer Institute, followed by academic appointments at the Icahn School of Medicine at Mount Sinai and at Charité University Medicine Berlin, Germany. Dr. Böttinger’s interdisciplinary research in digital health and personalized medicine combines digital technologies with molecular and data sciences. He has published extensively and in high-impact journals, and serves as founder and advisor in the health sector.
Co-Founder & Managing Director, OmicEra Diagnostics GmbH
Dr. Sophia Doll studied Molecular Biology at the University of Munich from which she also holds a Ph.D. in Biochemistry. During her doctoral thesis, she explored the scientific interconnections between industry, academia and the clinic. This journey took her to Genentech Inc., the University of California San Francisco (UCSF) and the Max Planck Institute of Biochemistry. Sophia co-authored more than 25 peer-reviewed publications and was a doctoral fellow of the elite German Academic Scholarship Foundation. She won the Max Planck Science Slam and beyond her scientific career, she is a passionate ski instructor.
Managing Director BioM Biotech Cluster Development GmbH
After earning his doctorate in biochemistry in 1979, Horst Domdey worked as a scientist at various German, Swiss and US institutes such as the Max Planck Institute of Biochemistry, the ISREC, the UCSD and the California Institute of Technology. From 1984 to 1994 he headed an independent research group at the Gene Center of the LMU Munich where he was appointed Professor of Biochemistry in 1994. In the same year he co-founded MediGene, one of the first German biotech companies. In 1996 he successfully led the Munich Biotech Initiative into the German BioRegio Competition. Since 1997 he has been the Managing Director of BioM, the cluster development and management organization of the Munich Biotech Cluster. Since 2006 he also oversees the Bavarian Biotechnology Network. From 2010 to 2015, he was the spokesman of the Munich leading edge cluster program m4 – Personalized Medicine m4. Among others he is member of the Supervisory Board of Medigene AG, of the Advisory Board of GNA Biosolutions, of the boards of the Peter and Traudl Engelhorn Foundation and the Foundation for Stem Cell Research and Applied Regenerative Medicine, of the Advisory Board of FCF Fox Corporate Finance, and of the Translational Research Group of the German Centre for Cardiovascular Research.
Founder-Director of the Research Centre for E-Health Law, University of Augsburg
After his education in Tübingen, Speyer and Oxford, Ulrich M. Gassner took on a professorship in public law at the Faculty of Law of the University of Augsburg in 1997. There he founded the Research Centre for Medical Device Law in 2005 and the Research Centre for E-Health Law in 2016. In addition, he has been a faculty member of the Munich Intellectual Property Law Center (MIPLC) since 2004. Ulrich M. Gassner is the author of over 150 publications in several areas of life sciences law and advises ministries, companies, associations and other institutions on these matters."
Bavarian State Minister of Health and Care
Professor for Digital Health, Institute for Informatik, Technische Universität München
Education and Academic Experience
2019 to present: Technical University of Munich, Munich, Germany Professor Digital Health
2014 to 2019: Uniklinik RWTH Aachen, Aachen, Germany Head of Division mHealth at the Department of Medical Informatics
2017 to 2019: Uniklinik RWTH Aachen, Aachen, Germany Head of Division Image Processing at the Department of Medical Informatics
2010 to 2014: Uniklinik RWTH Aachen, Aachen, Germany Doctoral student in theoretical medicine at the Department of Medical Informatics
2009 to 2012: Yale School of Medicine, Yale University, New Haven, CT, USA Lecturer in the Department of Diagnostic Radiology
Jun 2010 to Oct 2010: Reykjavik University, Reykjavik, Iceland Visiting researcher at the engineering department
2007 to 2009: Chair of Computer Science 6, RWTH Aachen, Germany Research assistant
2003 to 2009: RWTH Aachen University, Germany Diploma student in Computer Science, subsidiary medicine
CEO Bitcare GmbH
Dr. Florian Kohlmayer received his PhD from the Technical University of Munich, Chair of Medical Informatics of the Institute of Medical Informatics, Statistics and Epidemiology in cooperation with the Chair of Security in computer science. His interests include IT support for medical research, especially solutions for IT security and privacy. He is co-founder and CEO of Bitcare GmbH, which focuses on IT services for translational medicine.
Professor of Medical Informatics and Coordinator of DIFUTURE, TUM
Professor Kuhn’s research area is digital and translational medicine, with a specific focus on integration and security architectures. He and his team have developed innovative IT concepts and solutions in large national and international projects.
Professor Kuhn holds degrees in computer science, mathematics and medicine from the Universities of Stuttgart, Freiburg, Tübingen and Ulm. He worked at the University Hospitals of Heidelberg and Ulm. From 1996 to 2004 he held the Chair of Medical Informatics at the University of Marburg. In parallel to this he was Chief Information Officer of Marburg University Medical Center. Between 2007 and 2011 he was president and vice-president of the German Association for Medical Informatics, Biometry and Epidemiology. Professor Kuhn was elected a Fellow of the American College of Medical Informatics (AMIA) in 2008. Since 2016, he is coordinator of DIFUTURE, a consortium of the German Medical Informatics Initiative funded by BMBF.
Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University Munich
Lars Maegdefessel studied Medicine at the Johannes Gutenberg University in Mainz, the University of Bern (Switzerland), and the Albert Einstein College of Medicine (New York, USA). After receiving his doctorate and completing a clinical fellowship in cardiology, he joined the Division of Cardiovascular Medicine at Stanford University, USA. After spending 3 years as a postdoctoral researcher in Stanford, he accepted an appointment as an Assistant Professor of Molecular Vascular Medicine at the Karolinska Institute in Stockholm, Sweden. In spring 2016 he was recruited through a Heisenberg Professorship (Vascular Biology) to TUM where he leads a research group sponsored by the German Center for Cardiovascular Research (DZHK). His laboratories in Munich and Stockholm investigate the therapeutic and biomarker potential of non-coding RNAs in vascular diseases. The two main vascular pathologies in focus are abdominal aortic aneurysms as well as carotid artery disease and ischemic forms of stroke. The labs have access to various human biobanks, preclinical in vivo and in vitro models (organs-on-chips) and utilize Omics approaches to unravel novel molecular targets with relevance to vascular disease development and progression.
Director Department of Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry
Matthias Mann studied physics and mathematics at Göttingen University in Germany and obtained his Ph.D. in chemical engineering at Yale where his work contributed to the Nobel Prize for his supervisor John Fenn in 2012 for the development of electrospray ionization. Thereafter at the University of Southern Denmark he developed the first bioinformatic search algorithms for peptide fragmentation data and SILAC, a paradigm-shifting method of quantitative proteomics and a breakthrough in the mapping of protein interactions.
In 2005 Matthias Mann was appointed head of the Department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry, Martinsried near Munich and since 2009 has an additional appointment as director of the Department of Proteomics, Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen.
His work has been decisive in making mass spectrometry applicable to molecular biology. He has developed computer algorithms to match mass spectrometric data with sequence databases and introduced methods for accurate quantitation into proteomics and downstream biology. His team works in proteomics technology development and performs global large-scale proteomic and phosphoproteomic studies in different biological questions and medical fields.
The Mann laboratory is a technical leader in the field of mass spectrometry and has pushed the technology ever-deeper coverage of proteomes for over two decades. The group increasingly focusses on clinically relevant topics, especially the analysis of the blood plasma proteome. The establishment of a robust and reproducible high-throughput proteome profiling pipeline for the analysis of whole blood, plasma and serum samples will soon allow the proteomic screening of clinical cohorts for new biomarkers or biomarker patterns.
He has been elected as a member of EMBO, the Royal Danish Academy of Arts and Sciences and the Leopoldina German National Academy of Sciences. In 2012 he was awarded the Leibniz Prize from the German Research Foundation, the Ernst Schering Prize, the Louis-Jeantet Foundation Prize for Medicine and the Körber European Science Prize. In 2015 was awarded the Barry L. Karger Medal in Bioanalytical Chemistry and the Theodor Bücher Lecture and Medal as well as the Danish Order of Dannebrog Knights Cross and in 2019 was nominated as a member of the Bavarian Academy of Sciences and Humanities. He holds two honorary doctorates. He is author of over 700 publications and one of the most cited scientists worldwide with an h-factor of 237 and more than 260,000 total citations (Google Scholar).
Co-Founder, CEO and Chairman of the Board, docdok.health
Ulrich Muehlner is a senior healthcare executive with 20 years of industry experience and is particularly passionate about transforming the healthcare industry towards personalized and value-based healthcare through Digital Health & HealthTech solutions, in particular in the areas of Connected Care, Digital Therapeutics, Patient-Generated Health Data (PGHD) / Real World Evidence, and Artificial Intelligence / Deep Learning. In 2017, he co-founded docdok.health with the mission to deliver personalized healthcare through its innovative digital physician/patient communication platform docdok and also through regulatory-approved DiGAs (digital health applications ) as medical products in several areas. docdok.health has delivered several key digital solutions in connection with the coronavirus crisis, most prominently the DIFA1 app to accompany healthcare professionals after their COVID-19 vaccinations.
Dr Muehlner serves globally as board member/advisor to healthcare companies (e.g., in the space of AI for pharmaceutical drug R&D). Previously, Ulrich Muehlner worked at Novartis and the Boston Consulting Group (BCG). At Novartis, he was Global Head Corporate Strategy and Global Head Healthtech Partnerships, responsible for the multi-billion dollar portfolio transformation strategy and spearheaded globally the digital health activities across Novartis leading to major partnerships with Google/Verily, IBM, and several StartUps with the aim to better serve patients while increasing the value of the Novartis portfolio through ‘beyond-the-drug’ real-world outcomes solutions. In total, Mr Muehlner successfully executed deals with a volume of $350mn. Ulrich Muehlner studied Biochemistry in Hannover and Munich, and earned a PhD degree in Biochemistry and Molecular Biology based on his research on molecular mechanisms of cancer development at the Research Institute of Molecular Pathology (I.M.P.) in Vienna.
Director of the Institute of Epidemiology, Helmholtz Zentrum München
Annette Peters directs the Institute of Epidemiology at the Helmholtz Zentrum München – German Research Center for Environmental Health and is full Professor of Epidemiology at the Ludwig Maximilians Universität München, Germany. She studied biology and mathematics in Germany and epidemiology at the Harvard School of Public Health, Boston, USA. She pioneered work identifying the link between ambient particulate matter and cardiovascular disease. Today, she heads the population-based KORA cohort initiated in the mid-eighties in Augsburg, Germany and is a principal investigator of the German National Cohort, responsible for building its central biorepository. Since October 2018, she chairs the board of directors of the German National Cohort, which investigates prospectively 205,000 men and women. Her research interest are age-related and chronic diseases. Specifically, she strives to improve the understanding of disease development by integrating lifestyle and environmental factors, molecular and imaging markers to assess their relative impact on cardiometabolic diseases.
Bavarian Data Protection Commissioner
Thomas Petri has been the Bavarian State Commissioner for Data Protection, elected by the Bavarian State Parliament, since July 1, 2009.
After completing his doctorate of law, Thomas Petri moved to the Supervisory Authority Schleswig-Holstein in the summer of 2000. There, as head of unit, he was responsible for the supervision of the private sector. From 2004 to 2006, he was seconded to the Federal Constitutional Court, where he worked as a research assistant in the First Senate. He then took over as head of the Legal Department at the Berlin Commissioner for Data Protection and Freedom of Information; at the same time, I was deputy commissioner in this department. Since July 1, 2009, Thomas Petri has been the Bavarian State Commissioner for Data Protection. The State Commissioner is elected by the Bavarian State Parliament on the recommendation of the Bavarian State Government. He is appointed by the President of the State Parliament. The term of office is six years; he can be re-elected. The re-election of Thomas Petri took place on June 10, 2015. Since March 30, 2016, he has been an honorary professor at the University of Applied Sciences in Munich. Thomas Petri is an advisor and scientific co-editor in various legal journals with data protection law relevance.
Institute of Neurogenomics, Helmholtz Zentrum München
Professor of Artificial Intelligence in Healthcare and Medicine, TUM
Since 2020 Daniel Rueckert us the Alexander von Humboldt Professor for AI in Medicine and Healthcare at the Technical University of Munich. He is also Professor of Visual Information Processing in the Department of Computing at Imperial College London where he served as Head of the Department of Computing. He has gained a MSc from Technical University Berlin in 1993, a PhD from Imperial College in 1997, followed by a post-doc at King’s College London. In 1999 he joined Imperial College as a Lecturer, becoming Senior Lecturer in 2003 and full Professor in 2005. He has published more than 500 journal and conference articles with over 50,000 citations. He has graduated over 50 PhD students and supervised over 40 post-docs. He is an associate editor of IEEE Transactions on Medical Imaging, a member of the editorial board of Medical Image Analysis, Image & Vision Computing, MICCAI/Elsevier Book Series, and a referee for a number of international medical imaging journals and conferences. He has served as a member of organising and programme committees at numerous conferences, e.g. he has been General Co-chair of MMBIA 2006 and FIMH 2013 as well as Programme Co-Chair of MICCAI 2009, ISBI 2012 and WBIR 2012. In 2014, he has been elected as a Fellow of the MICCAI society and in 2015 He was elected as a Fellow of the Royal Academy of Engineering and as fellow of the IEEE. More recently he has been elected as Fellow of the Academy of Medical Sciences (2019).
Cardiology Department, German Heart Centre Munich
Coordinator of the Vroni-Study (www.myvroni.de)
Since 2014 Residency at the German Heart Center, Munich, Department of Cardiology
Medical degree at Ludwig-Maximilians-University (LMU), Munich
Qualification for genetic counselling (Internal Medicine)
Director of the Cardiology Department, German Heart Centre Munich
Heribert Schunkert, MD is Professor of Cardiology of the Technische Universität München and Director of the Cardiology Department, German Heart Centre Munich since 2012. He completed a research fellowship at Brigham and Women’s Hospital, Boston, USA and clinical fellowships at Beth Israel Hospital, Universitätsklinikum Regensburg, and the Massachusetts General Hospital, Boston, USA, before he became assistant and associate professor in Regensburg. From 2002-2012 Prof. Schunkert was Director of Internal Medicine and Cardiology at the University of Luebeck. He conducts research in the molecular genetics of multifactorial cardiovascular disease, coordinates several EU- and BMBF-sponsored projects as well as the European-American Leducq network CADgenomics to identify the genetic roots of myocardial infarction. He is the author of more than 700 publications in international journals.
Cardiology Department, German Heart Centre Munich
Since 2018 Cardiology Residency at the German Heart Centre Munich, Department of Cardiology
Medical degree at Medical School of the Technical University Munich, with trainings and stays at the University Hospital Zurich, Switzerland; New York Presbyterian Hospital, Weill Cornell Medical College, USA; German Heart Centre Munich, Germany and Rotkreuzklinikum München, Germany
Business Development Manager, Olink Proteomics GmbH
Karsten Strauß, PhD, is a trained biologist with the focus on human genetics, parasitology and virology at the University of Tübingen. Focusing during his PhD thesis on Parkinsons disease, he moved for his postdoctoral studies to the US, working at the Cedars-Sinai Medical Center in Los Angeles and the University of Utah in Salt Lake City working on other neurodegenerative diseases. Leaving the academic environment in 2010, he worked as an instrument specialist for biotech companies and started his position as a Business Development Manager at Olink Proteomics in 2016.
Chief Medical Officer and Co-Founder, iATROS GmbH
current Misc. medical-scientific and business projects
• Gerson Lehrman Group (GLG) Council Member
• Co-founder and director of Micropept Ltd. (startup to exploit own patents)
• Consultant for CellNetworX LLC (drug discovery startup), Co-PI on NIH Small
Business Innovation Research grant (SBIR)
• Consultant for McKinsey (analysis and evaluation of medical-scientific projects)
• Consultant for venture capital companies (due diligence of target companies)
• Fellow of the European Society of Cardiology, FESC (ESC)
• European Society of Cardiology Working Group on e-Cardiology
• German Cardiology Association (DGK), Working Group on Telemonitoring
• Association for Research in Vision and Ophthalmology (ARVO)
• Medizinisch-Naturwissenschaftliche Gesellschaft Wuppertal (MNG)
Cardiology Department, German Heart Centre Munich
• 2014 – current Resident for Internal Medicine and Cardiology, German Heart Center Munich (DHM) of the Technical University Munich, Germany, Medical Director Prof. Dr. H. Schunkert
• 2014 Surgery, Klinikum Rechts der Isar of the Technical University Munich, Germany
• 2014 Neurology, University Hospital of Zürich, Switzerland
• 2013 Pediatrics, University Hospital Großhadern, Munich, Germany
• 2013 Inner Medicine and Cardiology, University Hospital Großhadern, Munich, Germany
• 2013 Intensive-Care Medicine, University Hospital Großhadern, Munich, Germany
• 2013 General Medicine, AGZ, Altenmarkt, Austria
Research and work in progress
• 2015 – current Research on atherosclerosis – Supervisor and Medical Director Prof. Dr. H. Schunkert
• 2018 DZHK Clinician Scientist Programme – Identification and validation of key driver genes in atherosclerosis relevant networks.
• 2018 DigiMed Bayern. Scientific Co-PI: Multi-Omics in Atherosclerosis – approaching personalized medicine in CAD.
• 2016 Research fellow of the Departments of Medicine, Microbiology, Immunology, Molecular and Human Genetics, David Geffen School of Medicine, University of California Los Angeles, USA
• 2016 – 2018 “CADgenomics – Understanding CAD Genes programme” - supported by grants from the Fondation Leducq
• 2011 – 2014 Research fellow of the transplant-immunologic research laboratory Innsbruck, Austria Department of Visceral-, Transplant- and Thoracic-Surgery, University of Innsbruck,
von Scheidt M, Zhao Y, de Aguiar Vallim TQ, Che N, Franzén O, Kurt Z, Yamamoto M, Edwards PA, Kovacic J, Björkegren J, Lusis AJ, Yang X, Schunkert H. The transcription factor MAFF regulates an atherosclerosis relevant gene network. Accepted at Circulation
Schunkert H, Boening A, von Scheidt M, […] Hambrecht R, Kastrati A, Sandner S. Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. European Heart Journal. 2019 May 30. pii
von Scheidt M, Zhao Y, Kurt Z, Pan C, Zeng L, Yang X, Schunkert H, Lusis AJ. Applications and Limitations of Mouse Models for Understanding Human Atherosclerosis. Cell Metabolism. 2017 Feb 7;25(2):248-261.
Managed by BioM Biotech Cluster Development GmbH
Copyright © 2019 BioM Biotech Cluster Development GmbH
Alle Rechte vorbehalten